September 2026 consolidated quarter: revenue up 10%, profit after tax up 14% year on year
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
For the consolidated quarter ended September 30, 2026, revenue from operations was INR 8,059.35 million, up 10.2% from INR 7,313.98 million a year earlier, while profit after tax was INR 649.69 million, up 13.7% from INR 571.52 million. The operating margin before other income, interest, depreciation and tax widened from 18.6% to 23.2%. Bliss GVS Pharma was acquired on September 28, 2026. Comparative figures were regrouped and recast.
Sentiment may improve after double-digit revenue and profit growth and wider margins, but the new acquisition raises integration and execution risks.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.